PRINCETON, N.J., Oct. 29, 2007 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that executive management will participate in the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference to be held at the New York Palace Hotel in New York City during November 5 through November 7, 2007. Dr. Geert Cauwenbergh, Chief Executive Officer of Barrier, is scheduled to present an overview of the Company's commercial operations and development programs on Tuesday, November 6, at 10:15 a.m. EST.
The presentation will be available via a live webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. An archive of the presentation will be available for replay for 90 days.
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.